Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ALP6 | ISIN: US1850631045 | Ticker-Symbol: CLM
Tradegate
05.06.25 | 17:59
0,675 Euro
-2,88 % -0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARSIDE BIOMEDICAL INC Chart 1 Jahr
5-Tage-Chart
CLEARSIDE BIOMEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,6800,72006.06.
0,6750,71506.06.

Aktuelle News zur CLEARSIDE BIOMEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.05.Clearside Biomedical auf dem Stifel Forum: Strategische Schritte in der Augenheilkunde2
27.05.Clearside Biomedical target cut to $5 by H.C. Wainwright2
27.05.H.C. Wainwright senkt Kursziel für Clearside Biomedical auf 5 US-Dollar1
CLEARSIDE BIOMEDICAL Aktie jetzt für 0€ handeln
21.05.Clearside Biomedical, Inc.: Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum2
15.05.Stifel maintains Buy on Clearside Biomedical, target at $82
14.05.Clearside Biomedical GAAP EPS of -$0.11 in-line, revenue of $2.3M beats by $2.1M4
13.05.Clearside Biomedical Q1 2025 Earnings Preview6
13.05.A Peek at Clearside Biomedical's Future Earnings2
09.05.Clearside Biomedical, Inc.: Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting3
08.05.Clearside Biomedical, Inc.: Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 20253
23.04.JMP maintains $5 price target on Clearside Biomedical stock5
28.03.Stifel maintains Clearside Biomedical buy rating, $8 target5
28.03.JMP reiterates Clearside Biomedical stock with $5 target3
28.03.Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD2
27.03.Clearside Biomedical, Inc. - 8-K, Current Report1
27.03.Clearside Biomedical, Inc.: Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update252- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular...
► Artikel lesen
26.03.Exploring Clearside Biomedical's Earnings Expectations1
24.03.Clearside Biomedical, Inc.: Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting1
20.03.Clearside Biomedical, Inc.: Clearside Biomedical's Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit99- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs Rescue...
► Artikel lesen
12.03.Clearside Biomedical, Inc.: Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 202511
Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1